Erythropoietin Resistance in Anemia of Chronic Kidney Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00526747 |
Recruitment Status :
Completed
First Posted : September 10, 2007
Last Update Posted : April 11, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Anemia Kidney Failure Erythropoietin |
Study Type : | Observational |
Actual Enrollment : | 32 participants |
Official Title: | Novel Biomarkers of Erythropoietin Resistant Anemia Among Patients With Chronic Kidney Disease |
Study Start Date : | August 2007 |
Actual Primary Completion Date : | June 2008 |
Actual Study Completion Date : | June 2008 |

Group/Cohort |
---|
Epo-resistant
Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are receiving greater than or equal to 100IU/kg/week of epoetin alpha and/or 1mcg/kg/week darbepoetin to obtain target hemoglobin or hematocrit.
|
Epo-responsive
Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are requiring <100IU/kg/week of epoetin alpha and/or 1mcg/kg/week of darbepoetin to obtain target hemoglobin/hematocrit.
|

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- prevalent patients greater than or equal to 18 years old with CKD defined as a glomerular filtration rate < 60 cc/min
Exclusion Criteria:
- active GI bleeding or history of GI bleed in the prior 3 months
- uncontrolled hyperparathyroidism (PTH>500)
- untreated iron deficiency (transferrin saturation < 20% and ferritin < 100
- overt infection
- active hemolysis
- hemoglobinopathies
- known adverse response to erythropoietin
- prior kidney transplant
- aluminum toxicity

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00526747
United States, North Carolina | |
Durham Nephrology Anemia Clinic | |
Durham, North Carolina, United States, 27704 | |
Duke University Medical Center Anemia Clinic | |
Durham, North Carolina, United States, 27705 |
Principal Investigator: | Jula Inrig, MD, MHS | Duke University | |
Principal Investigator: | Lynda Szczech, MD | Duke University | |
Principal Investigator: | Suzanne K Bryskin, MD | Duke University |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Duke University |
ClinicalTrials.gov Identifier: | NCT00526747 |
Other Study ID Numbers: |
Pro00008469 |
First Posted: | September 10, 2007 Key Record Dates |
Last Update Posted: | April 11, 2013 |
Last Verified: | November 2008 |
Kidney Diseases Renal Insufficiency, Chronic Renal Insufficiency |
Anemia Hematologic Diseases Urologic Diseases |